Risk of residual/recurrent cervical diseases in HPV-positive women post-conization depends on HPV integration status

被引:0
作者
Lin, Wenyu [1 ,2 ,3 ]
Huang, Yuxuan [1 ,2 ,3 ]
Zhang, Yan [4 ]
Huang, Lixiang [1 ,2 ,3 ]
Cai, Hongning [5 ]
Huang, Guanxiang [1 ,2 ,3 ]
Li, Ye [6 ]
Zhang, Qiaoyu [7 ]
Xue, Huifeng [8 ]
Dong, Binhua [1 ,2 ,3 ,9 ]
Sun, Pengming [1 ,2 ,3 ,9 ]
机构
[1] Fujian Med Univ, Coll Clin Med Obstet & Gynecol & Pediat, Fuzhou 350001, Fujian, Peoples R China
[2] Fujian Women & Childrens Hosp, Fujian Matern & Child Hlth Hosp, Fujian Key Lab Women & Childrens Crit Dis Res, Fuzhou 350001, Fujian, Peoples R China
[3] Fujian Matern & Child Hlth Hosp, Fujian Obstet & Gynecol Hosp, Fujian Clin Res Ctr Gynecol Oncol, Fuzhou 350001, Fujian, Peoples R China
[4] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Fujian, Peoples R China
[5] Women & Childrens Hosp Hubei Prov, Maternal & Child Hlth Hosp Hubei Prov, Dept Gynecol, Wuhan 430070, Hubei, Peoples R China
[6] Zhengzhou Univ, Dept Obstet & Gynecol, Affiliated Hosp 3, Zhengzhou 450000, Henan, Peoples R China
[7] Mil Hosp 73rd Army Grp, Dept Gynecol, Xiamen 361003, Fujian, Peoples R China
[8] Fujian Med Univ, Fujian Matern & Child Hlth Hosp, Fujian Prov Cerv Dis Diag & Treatment Hlth Ctr, Affiliated Hosp, Fuzhou 350001, Fujian, Peoples R China
[9] Fujian Med Univ, Fujian Matern & Child Hlth Hosp, Coll Clin Med Obstet & Gynecol & Pediat, Lab Gynecol Oncol, 18 Daoshan Rd, Fuzhou 350001, Fujian, Peoples R China
来源
INFECTIOUS AGENTS AND CANCER | 2025年 / 20卷 / 01期
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
HPV integration; Cervical intraepithelial neoplasia; Post-treatment surveillance; HUMAN-PAPILLOMAVIRUS; CANCER; GUIDELINES; MANAGEMENT; LESIONS; HEAD; DNA;
D O I
10.1186/s13027-025-00637-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIt is crucial to identify post-operative patients with HPV infection who are at high risk for residual/recurrent disease. This study aimed to evaluate the association between HPV integration and clinical outcomes in HPV-positive women after cervical conization, as well as to identify HPV integration breakpoints.MethodsThis retrospective study analyzed data of 791 women who underwent cervical conization for cervical intraepithelial neoplasia grades 2-3 (CIN2-3) between September 2019 and September 2023, sourced from the Fujian and Hubei cervical lesion screening cohorts. Among these, 73 women with HPV infection post-conization underwent HPV integration test within 3 months after a positive HPV test. HPV integration test was performed using the high-throughput viral integration detection (HIVID), a sensitive method for genome-wide survey of HPV integration breakpoints.ResultsAmong the 73 participants with HPV infection post-conization, 10 cases (13.7%) were positive for HPV integration. The logistic regression analysis showed a higher residual/recurrent lesions risk in patients with HPV integration (OR = 3.917, p = 0.048). According to the Kaplan-Meier analysis, age >= 45 years (p = 0.016) and HPV integration (p = 0.035) were associated with a higher risk of residual/recurrent CIN at the 1-year follow-up. HPV 52 accounted for the majority of HPV integration genotype (3/10, 30.0%). Surprisingly, HPV 16 had the highest number of HPV average integration sequencing reads (n = 129), followed by HPV 31, 58, 52, 59, 35, and 39. The study also identified 13 HPV breakpoints, including TP63, TLR4, USP10, etc.ConclusionsHPV integration was identified as an independent risk factor for residual/recurrent CIN in HPV-positive women post-conization. Women with positive HPV integration should pay attention to careful post-treatment follow-up.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Age, margin status, high-risk human papillomavirus and cytology independently predict recurrent high-grade cervical intraepithelial neoplasia up to 6 years after treatment
    Andersson, Sonia
    Megyessi, David
    Belkic, Karen
    Alder, Susanna
    Ostensson, Ellinor
    Mints, Miriam
    [J]. ONCOLOGY LETTERS, 2021, 22 (03)
  • [2] Understanding the HPV integration and its progression to cervical cancer
    Araceli Oyervides-Munoz, Mariel
    Ali Perez-Maya, Antonio
    Frecia Rodriguez-Gutierrez, Hazyadee
    Sofia Gomez-Macias, Gabriela
    Raul Fajardo-Ramirez, Oscar
    Trevino, Victor
    Alberto Barrera-Saldana, Hugo
    Lourdes Garza-Rodriguez, Maria
    [J]. INFECTION GENETICS AND EVOLUTION, 2018, 61 : 134 - 144
  • [3] European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology
    Arbyn, M.
    Herbert, A.
    Schenck, U.
    Nieminen, P.
    Jordan, J.
    Mcgoogan, E.
    Patnick, J.
    Bergeron, C.
    Baldauf, J-J.
    Klinkhamer, P.
    Bulten, J.
    Martin-Hirsch, P.
    [J]. CYTOPATHOLOGY, 2007, 18 (03) : 133 - 139
  • [4] Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
    Arbyn, Marc
    Weiderpass, Elisabete
    Bruni, Laia
    de Sanjose, Silvia
    Saraiya, Mona
    Ferlay, Jacques
    Bray, Freddie
    [J]. LANCET GLOBAL HEALTH, 2020, 8 (02): : E191 - E203
  • [5] Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
    Arbyn, Marc
    Redman, Charles W. E.
    Verdoodt, Freija
    Kyrgiou, Maria
    Tzafetas, Menelaos
    Ghaem-Maghami, Sadaf
    Petry, Karl-Ulrich
    Leeson, Simon
    Bergeron, Christine
    Nieminen, Pekka
    Gondry, Jean
    Reich, Olaf
    Moss, Esther L.
    [J]. LANCET ONCOLOGY, 2017, 18 (12) : 1665 - 1679
  • [6] Integrated genomic and molecular characterization of cervical cancer
    Burk, Robert D.
    Chen, Zigui
    Saller, Charles
    Tarvin, Katherine
    Carvalho, Andre L.
    Scapulatempo-Neto, Cristovam
    Silveira, Henrique C.
    Fregnani, Jose H.
    Creighton, Chad J.
    Anderson, Matthew L.
    Castro, Patricia
    Wang, Sophia S.
    Yau, Christina
    Benz, Christopher
    Robertson, A. Gordon
    Mungall, Karen
    Lim, Lynette
    Bowlby, Reanne
    Sadeghi, Sara
    Brooks, Denise
    Sipahimalani, Payal
    Mar, Richard
    Ally, Adrian
    Clarke, Amanda
    Mungall, Andrew J.
    Tam, Angela
    Lee, Darlene
    Chuah, Eric
    Schein, Jacqueline E.
    Tse, Kane
    Kasaian, Katayoon
    Ma, Yussanne
    Marra, Marco A.
    Mayo, Michael
    Balasundaram, Miruna
    Thiessen, Nina
    Dhalla, Noreen
    Carlsen, Rebecca
    Moore, Richard A.
    Holt, Robert A.
    Jones, Steven J. M.
    Wong, Tina
    Pantazi, Angeliki
    Parfenov, Michael
    Kucherlapati, Raju
    Hadjipanayis, Angela
    Seidman, Jonathan
    Kucherlapati, Melanie
    Ren, Xiaojia
    Xu, Andrew W.
    [J]. NATURE, 2017, 543 (7645) : 378 - +
  • [7] Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization
    Costa, S
    De Simone, P
    Venturoli, S
    Cricca, M
    Zerbini, ML
    Musiani, M
    Terzano, P
    Santini, D
    Cristiani, P
    Syrjänen, S
    Syrjdnen, K
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 358 - 365
  • [8] The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology
    Darragh, Teresa M.
    Colgan, Terence J.
    Cox, J. Thomas
    Heller, Debra S.
    Henry, Michael R.
    Luff, Ronald D.
    McCalmont, Timothy
    Nayar, Ritu
    Palefsky, Joel M.
    Stoler, Mark H.
    Wilkinson, Edward J.
    Zaino, Richard J.
    Wilbur, David C.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2013, 32 (01) : 76 - 115
  • [9] Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study
    Dong, Binhua
    Chen, Lihua
    Lin, Wenyu
    Su, Yingying
    Mao, Xiaodan
    Pan, Diling
    Ruan, Guanyu
    Xue, Huifeng
    Kang, Yafang
    Sun, Pengming
    [J]. CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [10] dos Santos Aniusca Vieira, 2019, Asian Pac J Cancer Prev, V20, P1019